Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Brief Summary: This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.


Options:
A: Inclusion Criteria:

* female and male patients who have failed to respond to previous therapies for interstitial cystitis/painful bladder syndrome
* male patients who have failed to respond to previous therapies for chronic prostatitis/chronic pelvic pain syndrome

Exclusion Criteria:

* neurologic disorder affecting bladder
* bladder cancer, prostate cancer, or urethral cancer
B: Inclusion Criteria:

1. History of pain perceived in the region of the prostate and absence of other lower urinary tract pathology for a minimum of 3 out of the past 6 months. In addition, associated lower urinary tract symptoms, sexual function, psychological factors should be addressed.
2. Age 18 to 50 years
3. NIH Chronic Prostatitis Symptom Index (NIH-CPSI) total score≥ 15 (scale 0-43, and 0 means no symptom).

Exclusion Criteria:

1. Other urologic disease (for example, acute prostatitis, bacterial prostatitis, benign prostatic hyperplasia, prostate cancer, urinary tuberculosis, urinary tract infection)
2. Serious or acute diseases with heart, liver, kidney and blood system.
3. Patients who had received acupuncture or medication (including alpha-blockers or pain killers) treatment in the week prior to the baseline assessment
4. Patients without telephone number who cannot be connected during the follow-up
C: Inclusion Criteria:

* Symptoms of discomfort or pain in the pelvic region for at least a three (3) months period within the last six (6) months.
* Moderate overall score on the NIH-CPSI (overall score more than 15 out of a potential of 0-43 points)
* Diagnosed as having CPPS Category III
* Participant is willing to undergo 10 weeks of acupuncture treatment

Exclusion Criteria:

* History of prostate, bladder or urethral cancer.
* Inflammatory bowel disease (such as Crohn's disease or ulcerative colitis, but not irritable bowel syndrome).
* Undergone pelvic radiation or systemic chemotherapy, intravesical chemotherapy or intravesical BCG.
* Treated for unilateral orchialgia without pelvic symptoms.
* Active urethral stricture.
* Undergone TURP, TUIP, TUIBN, TUMT, TUNA, balloon dilation of the prostate, open prostatectomy or any other prostate surgery or treatment such as cryotherapy or thermal therapy.
* Neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.
* Liver disease.
* Diagnosed as acute or chronic bacterial prostatitis.
* History of urinary tract infection positive uropathogen for the past year.
* Taking medications which could affect the lower urinary tract function
* History of type 1 or 2 diabetes.
* Treated/currently undergoing treatment with acupuncture for any other illness including prostatitis for the past 6 months.
* Refusal to be needled or any form of bleeding disorder.
D: Inclusion criteria:

* Informed consent to participate in study.
* Have had a single negative prostate biopsy within 6 months prior to enrollment in study.
* Have a PSA (prostate specific antigen) between 2.5 and 10 if 50-60 years of age; or a PSA between 3.0 and 10 if over age 60.
* Ability and will to participate in study for 4 years.

Exclusion criteria:

* More than one previous negative prostate biopsy.
* History of prostate cancer.
* Previous prostate surgery.
* Inability to urinate requiring the need of a catheter during the previous 2 years.
* Any condition (other than benign prostatic hypertrophy) which may result in urinary symptoms or changes in urine flow rate.
* Cancer within previous 5 years (other than basal or squamous cell cancers of the skin).
* Any unstable serious medical condition.
* Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride (Avodart), testosterone, or drugs that can block the action of male hormones.

Answer: D